16.12.2021 Dermapharm Holding SE  DE000A2GS5D8

DGAP-Adhoc: Dermapharm Holding SE raises EBITDA forecast for the full year 2021


 

DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Change in Forecast
Dermapharm Holding SE raises EBITDA forecast for the full year 2021

16-Dec-2021 / 12:08 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation - MAR)

Dermapharm Holding SE raises EBITDA forecast for the full year 2021

Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the business development in November on the basis of the preliminary figures in its Management Board meeting today and decided to adjust the forecast for the financial year 2021. Accordingly, the Executive Board now expects Group EBITDA1 to grow by 70 to 75 percent compared to the previous year (previously: 50 to 60 percent). In addition, the Executive Board confirms the revenue forecast for the 2021 financial year of 15 to 20 percent growth compared to the same period of the previous year.

1 EBITDA is an alternative performance indicator that is not defined according to international accounting standards. The Company uses these metrics to allow for better comparability of the business over time and within the industry. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation (see Dermapharm page 31, Annual Report 2020).

>End of the Ad hoc announcement<

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
E-Mail: [email protected]


16-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1258883

 
End of Announcement DGAP News Service

1258883  16-Dec-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1258883&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 467,12 572,42 700,88 793,83 942,91 1.024,78 1.105,00
EBITDA1,2 108,60 139,63 168,53 184,52 354,07 344,87 308,00
EBITDA-Marge3 23,25 24,39 24,05 23,24 37,55 33,65
EBIT1,4 92,12 107,51 119,51 136,85 298,47 243,69 200,00
EBIT-Marge5 19,72 18,78 17,05 17,24 31,65 23,78 18,10
Jahresüberschuss1 77,74 75,23 77,81 85,93 208,90 132,62 128,00
Netto-Marge6 16,64 13,14 11,10 10,82 22,16 12,94 11,58
Cashflow1,7 86,74 159,13 100,61 131,10 250,37 288,53 0,00
Ergebnis je Aktie8 1,56 1,41 1,43 1,59 3,89 2,49 2,37
Dividende8 0,00 0,77 0,80 0,88 2,17 1,05 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Grant Thornton

INVESTOR-INFORMATIONEN
©boersengefluester.de
Dermapharm Holding
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2GS5D 32,640 Halten 1.757,34
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,00 21,20 0,59 18,44
KBV KCV KUV EV/EBITDA
3,60 6,09 1,71 7,93
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,05 1,05 3,22 05.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
15.05.2024 27.08.2024 15.11.2023 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-13,86% -19,64% -22,91% -13,42%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Dermapharm Holding SE  ISIN: DE000A2GS5D8 können Sie bei EQS abrufen


Gesundheit , A2GS5D , DMP , XETR:DMP